Seratrodast
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Seratrodast: From Bronchial Asthma to Migraine (Susceptibility, With or Without Aura)
One-Sentence Summary
Seratrodast is a thromboxane A2 (TXA2) receptor antagonist approved in Japan for bronchial asthma; it currently holds no market authorization in India. The TxGNN model predicts it may be effective for migraine with or without aura, susceptibility to, but this prediction is currently supported only by indirect genetic/mechanistic literature on epilepsy-migraine comorbidity — no clinical trials and no drug-specific studies exist for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bronchial asthma (approved in Japan; not registered in India) |
| Predicted New Indication | Migraine with or without aura, susceptibility to |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Seratrodast is a selective thromboxane A2 (TXA2) receptor antagonist, approved in Japan for the treatment of bronchial asthma. TXA2 is a potent vasoconstrictor and platelet-activating eicosanoid; by blocking the TXA2 receptor, seratrodast reduces bronchoconstriction and airway inflammation in asthma.
The link to migraine draws on a historical “thromboxane/platelet activation hypothesis” of migraine pathophysiology, which proposed that TXA2-mediated vasospasm and platelet aggregation contribute to migraine attacks. Under this theory, TXA2 receptor antagonism could plausibly reduce cerebrovascular spasm associated with migraine. This is a coherent pharmacological hypothesis, but it remains indirect and untested — no study has evaluated seratrodast itself in migraine patients or migraine models.
The literature currently associated with this prediction largely concerns shared genetic susceptibility between epilepsy and migraine (e.g., ion channel polymorphisms, familial linkage studies), rather than TXA2 biology or seratrodast pharmacology. This evidence supports the biological plausibility that migraine has an underlying vascular/neuronal susceptibility component, but it does not directly validate the drug-disease link proposed by the model.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33856647 | 2021 | Review | Molecular Neurobiology | Reviews shared genetic and molecular mechanisms between epilepsy and migraine; discusses therapeutic strategies for comorbid disease, but does not mention TXA2 or seratrodast |
| 23294289 | 2013 | Genetic association study | Epilepsia | Investigated shared genetic susceptibility to migraine and epilepsy in the EPGP cohort; supports a genetic vascular/neuronal susceptibility model for migraine |
| 17460155 | 2007 | Genetic linkage study | Neurology | Mapped a familial locus (chromosome 9q) linking occipitotemporal lobe epilepsy with migraine with visual aura |
| 22266888 | 2011 | Review | Seminars in Neurology | General review of epilepsy genetics; background on genetic susceptibility mechanisms, not migraine- or TXA2-specific |
| 24076350 | 2014 | Meta-analysis (genetic polymorphism) | Gene | SCN1A polymorphism meta-analysis for febrile seizure-associated epilepsy susceptibility; not migraine- or drug-specific |
| 30267335 | 2018 | Meta-analysis (genetic polymorphism) | Neurological Sciences | MTHFR C677T polymorphism and epilepsy susceptibility; general genetic susceptibility background |
| 33187755 | 2021 | Meta-analysis (genetic polymorphism) | Clinical Neurology and Neurosurgery | KCNJ10 variant association with epilepsy susceptibility; unrelated to TXA2 pathway |
| 34575901 | 2021 | Review | Int J Molecular Sciences | Reviews molecular targets for antiepileptogenesis; general background, not migraine-specific |
Note: None of the retrieved literature directly studies seratrodast or TXA2 receptor antagonism in the context of migraine. The evidence base for this indication is limited to disease-susceptibility genetics for epilepsy/migraine comorbidity and is best classified as mechanistic/background support rather than direct evidence.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is at Evidence Level L5 — a model score only, with no clinical trials, no drug-specific preclinical studies, and no India market presence for seratrodast. The associated literature addresses migraine-epilepsy genetic comorbidity rather than TXA2 pharmacology, so the mechanistic hypothesis remains unvalidated.
To proceed, the following is needed:
- Confirmed mechanism-of-action data from DrugBank (currently a data gap, High severity)
- India/Taiwan regulatory label warnings and contraindications (currently a Blocking data gap — required before any S1 safety assessment)
- Preclinical or pilot clinical evidence directly evaluating TXA2 receptor antagonism in migraine models or patients
- Drug-drug interaction (DDI) profile, currently not found in available sources
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.